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Abstract
Allergy today is a public health concern of pandemic proportions, affecting more than 150 million people in Europe
alone. In view of epidemiological trends, the European Academy of Allergy and Clinical Immunology (EAACI)
predicts that within the next few decades, more than half of the European population may at some point in their
lives experience some type of allergy.
Not only do allergic patients suffer from a debilitating disease, with the potential for major impact on their quality
of life, career progression, personal development and lifestyle choices, but they also constitute a significant burden
on health economics and macroeconomics due to the days of lost productivity and underperformance. Given that
allergy triggers, including urbanization, industrialization, pollution and climate change, are not expected to change
in the foreseeable future, it is imperative that steps are taken to develop, strengthen and optimize preventive and
treatment strategies.
Allergen specific immunotherapy is the only currently available medical intervention that has the potential to affect
the natural course of the disease. Years of basic science research, clinical trials, and systematic reviews and
meta-analyses have convincingly shown that allergen specific immunotherapy can achieve substantial results for
patients, improving the allergic individuals’ quality of life, reducing the long-term costs and burden of allergies, and
changing the course of the disease. Allergen specific immunotherapy not only effectively alleviates allergy
symptoms, but it has a long-term effect after conclusion of the treatment and can prevent the progression of
allergic diseases.
(Continued on next page)
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Unfortunately, allergen specific immunotherapy has not yet received adequate attention from European institutions,
including research funding bodies, even though this could be a most rewarding field in terms of return on
investments, translational value and European integration and, a field in which Europe is recognized as a worldwide
leader. Evaluation and surveillance of the full cost of allergic diseases is still lacking and further progress is being
stifled by the variety of health systems across Europe. This means that the general population remains unaware of
the potential use of allergen specific immunotherapy and its potential benefits.
We call upon Europe’s policy-makers to coordinate actions and improve individual and public health in allergy by:
 Promoting awareness of the effectiveness of allergen specific immunotherapy
 Updating national healthcare policies to support allergen specific immunotherapy
 Prioritising funding for allergen specific immunotherapy research
 Monitoring the macroeconomic and health economic parameters of allergy
 Reinforcing allergy teaching in medical disciplines and specialties
The effective implementation of the above policies has the potential for a major positive impact on European
health and well-being in the next decade.
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Allergy Today: A public health threat of pandemic
proportions
At the beginning of the 20th century, allergy was viewed as
a rare disease. Since then, several incompletely understood
factors have triggered a dramatic increase more evident
over the last four decades. Initially, the highest prevalence
was in Westernized societies: and current estimates sug-
gest that up to 30% of Europeans could suffer from allergic
rhinitis or conjunctivitis, up to 20% of children from
asthma, 15% from allergic skin conditions and 8% from
food allergy. In other regions of the world, the prevalence,
which was previously low, is now increasing [1-3]. The
burden peaks in the 20–40 year old age group with clinical
symptoms of rhinitis reaching 45%. The worldwide num-
bers are equally worrying. Almost half a billion people suf-
fer from rhinitis [4,5] and approximately 300 million from
asthma [6]. Since many patients do not report their symp-
toms or are not properly diagnosed, the actual size of the
problem could be even larger. Taking into account the up-
ward trends shown by epidemiological studies, EAACI
predicts that within the next few decades more than half
of the European population will suffer from some type of
allergy [7,8].
The problem does not lie simply with respiratory aller-
gies. Food allergies are also becoming more frequent
and severe. Occupational allergies, drug allergies and al-
lergic reactions to the venom of stinging insects (which
can be potentially fatal) add further complexity and con-
cerns. Finally, new types of allergic diseases and allergies
against previously non-allergenic substances are being
increasingly reported.
The impact of allergic disease is detrimental both
for individual sufferers, their carers and for society as
a whole. Patients face impairment in their quality of
life, their sleep and mood, their competence at work
or school and their overall personal development. So-
ciety now confronts increasing associated costs on a
scale that will soon become unaffordable. With a
current estimate of more than 150 million patients
and a prediction of more than 300 million in Europe
in the next decade, allergies constitute a public health
concern of pandemic proportions requiring immediate
action [8-12].
The impact of allergy on the quality of life of Europeans
At a public health level allergic diseases have a detri-
mental impact on personal development, career progres-
sion and lifestyle choices for patients and their families.
People with allergic conditions are at a disadvantage,
which affects their school performance, work perform-
ance and social life.
Children with allergy demonstrate difficulty in coping
at school and develop associated learning difficulties and
sleeping problems [13]. As a result, it has been observed
that sleepiness and mood swings frequently lead children
to be isolated, perform less at school [14] and even get
bullied by their peers. Family life and personal relations
are subsequently disturbed [15-17].
Adult and adolescent patients also face a significantly
higher amount of problems in their workplace due to
increased sick days and productivity reduction [18]. Cog-
nitive functions are impaired and can be especially detri-
mental for school, university or work performance
[15,16,19]. Finally, several studies have shown that aller-
gic individuals have a higher risk of developing depres-
sion [20] as well as higher risk of depression in mothers
with an asthmatic child [21].
Calderon et al. Clinical and Translational Allergy 2012, 2:20 Page 2 of 8
http://www.ctajournal.com/content/2/1/20
The impact of allergies on the quality of life of suf-
ferers can be as high, or higher, than diseases that are
perceived as more ‘serious’ (i.e. diabetes). Lately, physi-
cians and scientists have been utilizing a set of specific
tools in order to evaluate the different domains of qual-
ity of life of allergic patients. The findings stemming
from this make us realize the extent of the issues and
underline the urgent need for solutions. By focusing on
quality of life as a key impact of allergies and asthma, we
will be able to give European patients renewed access to
optimism. In addition, we should never forget that a
small yet significant proportion of allergic reactions
might result in death; people at risk need to be priori-
tized and protected.
The impact of allergy on health economics and
macroeconomics
The associated reduction in productivity and the rising
number of sick days taken by allergic patients represents
one of the biggest negative impacts on national, business
and health economies in Europe [22,23].
Allergy health costs and their continuing escalation
have an adverse effect on the European economy due to
both direct costs (e.g. in the context of considering
asthma alone, pharmaceutical costs stands at €3.6 billion
per year and health care services at a further €4.3 billion
per year) [24] and, perhaps even greater, indirect costs.
In total, 15% of the population is receiving long-term
treatment in Europe for allergies and/or asthma, making
it the most common reason for a long-term treatment in
children and young people [25]. Among the direct med-
ical costs, the primary components are diagnostic tests,
consultations and medication, while an additional major
cost item is hospitalization, usually associated with se-
vere exacerbations of asthma or severe anaphylactic
reactions [25,26].
Moreover, performance deficits, loss of productivity
and absenteeism are closely linked to allergy suffering
and have a major effect on macroeconomics. Asthma
and rhinitis are estimated to result in more than 100
million lost workdays and missed school days each year
in Europe (not only children absent from school on any
given day, but also parents' productivity or absence from
work) [27-29].
Recently, it became apparent that in addition to absen-
teeism, hundreds of millions of Euros are also lost by
“presenteeism”, a condition in which people go to work,
but are unable to perform to their optimum capacity.
The total cost of asthma alone is estimated at more than
€25 billion annually [24]. The cost of rhinitis is probably
higher but, unfortunately, large scale socioeconomic
studies in Europe are lacking. Unpublished investigations
by the European allergy network GA2LEN calculate the
current loss due to untreated allergic rhinitis-related
presenteeism to be approximately a €100 billion annually
to employers [30]. This is based on employment figures
from European statistics, but does not measure the loss
to society due to presenteeism at schools or universities.
Understanding and monitoring the costs of allergic dis-
eases should be a priority and all health care systems
should take into account the rapid increase in preva-
lence, increase in severity and cost of allergies as they
may receive unsustainable demands from these condi-
tions alone.
The unsustainability of allergy’s current symptomatic
treatments
Currently, allergies are in most cases treated by short-
term symptom relieving or long-term anti-inflammatory
drugs [31-33]. The introduction of the latter, of which
corticosteroids are the most prominent, has reduced
some of the more serious outcomes of these diseases
[34]. However, important drawbacks in regard to
pharmacotherapy have also become evident: firstly, the
effectiveness of current medications in controlling
allergy symptoms is suboptimal [35]. Even under the
well-controlled conditions of a clinical trial, and after
optimizing treatment, a considerable proportion of
patients, sometimes even higher than 50%, will continue
to experience troublesome symptoms [35]. Secondly,
and most importantly, even after years of a continuous,
effective treatment, symptoms relapse very shortly after
ceasing daily use of medication [31]. Finally, long-term
use of drug treatment increases the possibility, but also
the fear, of adverse effects [36,37]. This is unacceptable
for patients who respond with a characteristic lack of
compliance to medical advice and frequently resort to
non-proven – and often expensive – complementary
and alternative ‘treatments’ with poor results and which
even may, if anything, exacerbate the problem [38].
With the increasing costs of newer medications and in-
creasing number of sufferers, this continuous dependence
on drugs is unsustainable. Both patients and physicians
call for more effective symptom control, but also for treat-
ments with long-term effects: a cure of the disease is what
should be the target for researchers and public health de-
cision makers in the coming years.
The promise for a cure and the role of allergen specific
immunotherapy
Aspects of modern-day European lifestyle, including
dietary patterns, urban living, industrialization, exposure
to cigarette smoke and other pollutants, and several
other factors, are major triggers of symptoms in allergic
patients and these are not expected to change on a sig-
nificant scale within the next few years. It is therefore
important to strengthen and optimize preventive and
treatment strategies. This has been clearly stated in the
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EU Sustainable Development Strategy; all European citi-
zens should have the means to improve their quality of
life, and mental and physical health, and have access to
the best preventive measures [39].
Allergen specific immunotherapy with preparations
which have confirmed effectiveness and tolerability in ad-
equate studies covering the specific claims made, is ef-
fective in alleviating allergy symptoms to a similar (or
even larger) extent than pharmacological treatments for
asthma [40], allergic rhinitis [41,42] and allergic conjunc-
tivitis [43]. At present it is the only curative treatment for
Hymenoptera (bee and wasp) venom allergy. Unlike
symptomatic medications, the benefits of allergen spe-
cific immunotherapy continue several years after discon-
tinuation of the treatment [44-46]. Moreover, specific
products for allergen specific immunotherapy have
shown to have disease-modifying capacities being able to
prevent the progression of allergic diseases, as in the case
of hay fever that may frequently lead to asthma [47-51]
and to reduce the risk of new sensitizations. Recent stud-
ies have shown that allergen specific immunotherapy has
a role in the treatment of food allergy in order to reduce
the risk of fatal anaphylaxis. Therefore, allergen specific
immunotherapy is currently the only medical interven-
tion that could potentially reverse the increasing disease
trends being seen in Europe and elsewhere.
Allergen specific immunotherapy has been used as a
medical treatment for over a century [52], offered mostly
to the more severe or difficult patients, in whom use of
medications is unsatisfactory, either because of lack of
efficacy or because of unacceptable untoward effects.
Currently, it is used only as a second-line treatment
[53]. However, in recent international guidelines and
academic position statements, it has been advocated for
use in those with milder disease in order to prevent
chronic irreversible structural changes in the airways.
Allergen specific immunotherapy should thus be consid-
ered as a treatment strategy in those with early-onset
and/or mild disease in order to maximise the potential
for the all-important disease-modifying capacities [4,53].
Major technological advances in the quality and for-
mulation of extracts used, new and more patient-
friendly delivery systems and a deeper understanding of
the mechanisms of allergic diseases have all led to the
expectation of a major breakthrough in allergy treat-
ment, in which allergen specific immunotherapy should
play a crucial role.
What allergen specific immunotherapy can achieve
Allergen specific immunotherapy holds considerable
promise for patients and, by extension, for society as a
whole. When used properly, following careful diagnosis,
and with good quality, well-characterized and clinically
documented extracts, it can transform the life of people
living with allergic diseases.
For patients
Allergen specific immunotherapy has been found to be
effective in reducing symptoms of allergic rhinitis and al-
lergic asthma and improving the quality of life of allergy
sufferers. It also results in reduced use of symptom re-
lieving medications. Allergen specific immunotherapy
has the potential for important longer-term benefits,
even after cessation of the treatment. In patients with al-
lergy to insect venom or food allergy, allergen specific
immunotherapy is able to prevent life-threatening reac-
tions. Different routes for allergen specific immunother-
apy have been evaluated, such as the subcutaneous,
sublingual, oral, nasal, bronchial, and intra-lymphatic,
the first two of these routes being the most commonly
used in clinical practice today. The most common aller-
gens used in clinical practice are aero-allergens for sea-
sonal and perennial allergy; more recently, latex and
food allergens have been evaluated in clinical trial with
promising results to be confirmed [54].
For clinicians
Both allergy specialists and general internists/family
physicians benefit from a therapeutic intervention that
not only reduces symptoms in their patients, but also
gives strong hope that the underlying allergy will be
cured and/or stopped in its progression. Especially in
children in whom the prospect of one allergy following
the other (the ‘allergic march’) is ever present, it also
offers a way for putting a break on this process, by
preventing the progression from, for example, allergic
rhinitis to asthma.
For public health
Allergen specific immunotherapy is currently the only
treatment that offers the possibility of reducing long-
term allergic disease burden and thereby the considerable
costs associated with treatment; this is achieved by bene-
ficially altering the natural course of the disease. Several
pharmaco-economic studies have shown important bene-
fits even from early time points, with steady increase with
time. It is conceivable that further research may lead
to preventive vaccination for allergies, as is now well-
established in relation to many infectious diseases.
Long-term effects of allergen specific immunotherapy
There is encouraging emerging evidence that children
receiving allergen specific immunotherapy for allergic
rhinitis develop considerably less asthma 10 years later,
in comparison to children that do not (control)[47], sup-
porting the case for allergen specific immunotherapy in
preventing progression of allergies to more severe forms.
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Given the considerable potential associated with this
immune-modulatory treatment approach, this is an area
in which there is a need for considerably more research.
Major milestones for allergen specific immunotherapy
It has taken considerable time to reach the current de-
gree of effectiveness and safety of allergen specific im-
munotherapy. Several appropriately designed clinical
trials have proven the effectiveness of allergen specific
immunotherapy of specific products in allergic rhinitis,
asthma and venom allergy. Such trials have not been
easy to design and perform for many reasons: extracts,
populations, dosing schedules, disease localization, and
allergen exposure are among the factors that vary con-
siderably and have to be taken into account [55-57].
Nevertheless, different independent systematic reviews
and meta-analyses of blinded randomized controlled
studies have consistently confirmed efficacy and effect-
iveness; with the recent large phase III trials, allergen
specific immunotherapy has moved from experience and
dogma to evidence based medicine and facts [58,59].
Furthermore, long-term effects have been repeatedly
shown, after treatment cessation. Based on these find-
ings, national and international evidence-based guide-
lines have been developed in order to assist practising
physicians in selecting the appropriate patients and pre-
parations and in optimizing treatment.
To this end, the continuous improvement of technolo-
gies that lead to high quality extracts and formulations
have had a major beneficial impact on both safety and
efficacy of allergen specific immunotherapy. Moreover,
the new delivery routes, such as sublingual allergen im-
munotherapy, have further added to the armamentarium
of allergy specialists, offering more convenient solutions
and high safety.
Molecular allergology is expected to take the field to
the next step, as the components of treatment will be
defined to precision in quality and quantity.
Major bottlenecks for further diffusion of allergen specific
immunotherapy
Extensive further research is needed to maximize the po-
tential of allergen specific immunotherapy:
 Even small changes in dose schedules may affect
results both in efficacy and safety. The potential
schemes are numerous and should be examined
comprehensively.
 The design of the studies, their analysis and how to
interpret their results should be refined bearing in
mind that pharmacotherapy and immunotherapy of
allergic diseases have commonalties and differences.
 Although we are much closer than ever to
understanding the basic mechanisms of allergen
specific immunotherapy, there are still several open
questions which, if answered, would enable us to
manipulate immune responses that are already
established.
 New extract preparations and especially vaccines
containing molecular components require validation.
The complexity of possible component
combinations requires novel bioinformatic
approaches. Studies exploring cost-effectiveness of
allergic rhinitis and asthma are still lacking and
should be assessed in relation to the various health
systems across Europe. The macro-economic impact
of allergies and the long-term cost-effectiveness of
allergen specific immunotherapy need further
detailed evaluation and attention.
Although it represents one of the most rewarding
fields in terms of return on investments, translational
value and European integration, allergen specific im-
munotherapy has not received adequate attention from
European research funding bodies. It is a field in which
Europe is already recognized as a leader worldwide and
it is important that we now capitalize on this leadership
position.
Awareness of allergen specific immunotherapy and its
treatment potential is inadequate in the general popula-
tion. In some cases immunotherapeutic approaches are
mistakenly considered to be ‘alternative’, non-proven
treatments.
Call for action
Allergic diseases, including asthma, are amongst the
top smoldering risks of global healthcare. The need
to deploy effective treatment solutions such as aller-
gen specific immunotherapy to stop and potentially
reverse allergy’s impact on European health, well-
being and macroeconomics is more urgent than ever
before.
We call upon Europe’s policy makers to co-ordinate
actions and improve individual and public health in al-
lergy by:
Promoting allergen specific immunotherapy awareness
The pandemic dimensions of allergic diseases highlights
the need for awareness at all levels. Millions of patients
who see little or no improvement with symptomatic
drug treatments, or wish to adopt a more curative ap-
proach to their illness can benefit from allergen specific
immunotherapy and should therefore be aware of the
availability and benefits of such treatment. Awareness
campaigns, and patient educational programs at pan-
European or national levels, should be promoted in
order to maximize the effects of the treatment on
Europe’s population.
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Update national healthcare policies to support allergen
specific immunotherapy
The huge socio-economic burden of allergic disease
calls for setting priorities. By prioritizing allergen spe-
cific immunotherapy in health planning and by design-
ing healthcare policies that support allergen specific
immunotherapy treatments of allergy through national
health insurance subsidization, long-term effects of al-
lergic diseases at a national, social and individual level
will be substantially reduced. The prevention of allergic
diseases can result not only in significant cost reduc-
tion, but also in a major improvement of the quality
of life of Europeans.
Prioritize funding for allergen specific immunotherapy
research
There has in recent years been tremendous progress in
effectively diagnosing and treating specific allergies.
Treatment approaches can and should be optimized. In-
novative approaches are underway. Recent advances in
molecular technology are destined to revolutionize im-
munotherapy treatments. Allergen specific immunother-
apy research needs to be catalyzed by European research
funding schemes, as the majority of current funding
derives from the industry, thus focusing only on part of
the treatment’s full capacity.
Monitoring the macroeconomic and health economic
parameters of allergy
There is a need for cost-benefit, cost-effectiveness and
cost-utility analyses as allergic diseases are increasingly
affecting large numbers of people with substantial cost
implications. This is an important part of the need to
monitor allergies in general, taking into account the
rapid changes in prevalence and their widespread
implications. Treatments like allergen specific immuno-
therapy that can combat both the symptoms and the
long-term consequences can be more cost effective
than routine health care by breaking the vicious circle
of living with allergies and coping with prolonged peri-
ods of suffering and medical treatment.
Streamline medical disciplines and specialties
Health systems around Europe differ widely in regard to
the provided services and range of health care profes-
sionals who address allergies. This results in insufficient
and unequal access to allergy services. Allergen specific
immunotherapy is a highly specialized value-added treat-
ment that can only be delivered by allergy specialists.
However, the enormous number of allergic patients
requires a wide range of health care professionals to be
constantly trained and informed of new evidence as well
as being equipped with appropriate tools to adequately
respond to the expanding allergy incidents and patients’
needs.
The effective implementation of the above policies
would have a major positive impact in European health
and well-being in the years to come.
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